Authors
Latest:
Dr. Khaled on Recognition and Treatment of TA-TMASamer K. Khaled, MD, discusses current recognition and treatment strategies for transplant-associated thrombotic microangiopathy.
Latest:
Dr. Khleif on Next Steps to Take With ImmunotherapySamir N. Khleif, MD, director, GRU Cancer Center, discusses next steps researchers and physicians need to take with immunotherapy in the field of oncology.
Latest:
Dr. Parekh on Using Genomics in Multiple Myeloma TreatmentSamir Parekh, MBBS, discusses using genomics to treat patients with multiple myeloma.
Latest:
Dr. Parekh on Potential Biomarker for Novel Drug in MyelomaSamir Parekh, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses a promising potential biomarker for response to selinexor in patients with myeloma.
Latest:
Dr. Taneja Discusses Multiparametric MRI in Prostate CancerSamir Taneja, MD, James M. Neissa and Janet Riha Neissa professor of urologic oncology, vice chair, Department of Urology, professor, Department of Radiology, co-director, Smilow Comprehensive Prostate Cancer Center, director, Urologic Oncology, Genito-Urologic program leader, NYU Langone’s Perlmutter Cancer Center, discusses multiparametric MRI in prostate cancer.
Latest:
Clinical Updates for the Management of Lung Cancer Brain MetastasesAs improved cancer therapies are helping patients live longer, the safe and effective management of lung cancer brain metastases is coming to the fore.
Latest:
Cervical Cancer Screening Overuse and Underuse: Patient and Physician FactorsFor a decade, US medical professional organizations and the US Preventive Services Task Force have suggested that low-risk women (history of multiple normal Papanicolaou [pap] tests, age over 30 years) receive cervical cancer screening every 3 years as part of routine preventive services.
Latest:
Samuel Smith on Adherence in Menopausal Women at Risk for Breast CancerSamuel Smith, PhD, university academic fellow at the University of Leeds, discusses a breast cancer prevention trial that measured adherence to preventative medication in women experiencing menopausal symptoms.
Latest:
Dr. Waxman on Advancements in Acute Promyelocytic LeukemiaSamuel Waxman, MD, Distinguished Service Professor of Medicine, Hematology and Medical Oncology, Distinguished Service Professor of Oncological Sciences, Mount Sinai Health System, discusses advancements in treating patients with acute promyelocytic leukemia.
Latest:
Dr. Memarzadeh on the Potential for Frontline Combinations in Ovarian CancerSanaz Memarzadeh, MD, PhD, discusses the potential for frontline combination therapy regimens in ovarian cancer.
Latest:
Dr. Sancy Leachman on Helping Patients Identify Melanoma RecurrencesSancy Leachman, MD,PhD, Professor and Chair, Department of Dermatology Director, Melanoma Research Program, Knight Cancer Institute, Oregon Health & Science University, discusses a new tool that oncologists can use with patients to identify melanoma recurrences.
Latest:
Dr. Pruthi on What She Learned From the Flaxseed TrialDr. Sandhya Pruthi from the Mayo Clinic in Minnesota on What She Learned From the Flaxseed Trial
Latest:
FDA Approval Insights: Perioperative Durvalumab for Resectable NSCLCDrs Patel and Stiles discuss the significance of the FDA approval of perioperative durvalumab for patients with resectable non–small cell lung cancer.
Latest:
Dr Patel on the FDA Approval of Durvalumab Plus Chemotherapy for NSCLCSandip P. Patel, MD, discusses the FDA approval of perioperative durvalumab plus chemotherapy for patients with non–small cell lung cancer.
Latest:
Dr. Cuellar on Concerns With Extrapolating Data for BiosimilarsSandra Cuellar, PharmD, BCOP, discusses challenges with data extrapolation for biosimilars.
Latest:
Dr. Sandra Demaria on Radiation and Immunotherapy Combination RegimensSandra Demaria, MD, assistant professor of Radiation Oncology, (Interim), Radiation Oncology, Weill Cornell Medical College and New-York Presbyterian, discusses the synergy with radiation therapy and immunotherapy as a potential combination regimen for patients with cancer.
Latest:
IDO Inhibitor/Chemo Combo Shows Early Promise in Advanced Pancreatic CancerNathan Bahary, MD, discusses results of a study that showed that the combination of indoximod with standard chemotherapy yielded a response rate of 42% as a first-line therapy for patients with metastatic pancreatic adenocarcinoma.
Latest:
Immunotherapy Shows Early Promise in Advanced SarcomasPhase Ib/II research has shown promise for adoptive cellular therapy combined with ipilimumab in patients with advanced sarcomas.
Latest:
Immunotherapy: Personalized Treatment for Advanced Prostate CancerIn April 2010, the FDA approved sipuleucel-T for patients with castration-resistant and metastatic prostate cancer, providing a new treatment that would help the body fight its own cancer.
Latest:
HER2-low Breast Cancer: Practical Applications of ADC TherapyPractical considerations for the sequencing or combination of novel antibody drug conjugates to optimize outcomes for patients with HER2-low breast cancer.
Latest:
Novel Molecular Targets for Drug Development in Non-GIST SarcomasThe characterization of molecular abnormalities implicated in the tumorigenesis of sarcomas is being increasingly applied to the classification, prognostication and, in particular situations, management of these diseases.
Latest:
Dr. D’Angelo on the Incidence and Prognosis of Merkel Cell CarcinomaSandra P. D’Angelo, MD, discusses the incidence and prognosis of patients with Merkel cell carcinoma.
Latest:
Dr Srinivas on the Role of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPCSandy Srinivas, MD, discusses the role of lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer.
Latest:
Improving Cancer Survivorship: Embedding Tailored, Comprehensive Survivorship Care in the Breast Oncology ClinicAnn Partridge, MD, MPH, from Dana-Farber Cancer Institute and Sandy Truong, a Harvard Medical School student, discuss the needs of cancer survivors and their efforts to optimize survivorship care.
Latest:
Dr. Wong on Treatment Goals in Systemic AmyloidosisSandy Wong, MD, discusses treatment goals for patients with systemic amyloidosis.
Latest:
Sangeetha Palakurthi on FDA Approval of Atezolizumab in NSCLCSangeetha Palakurthi, PhD, head of the Cancer Biology and Pharmacology Group at the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, discusses the FDA approval of atezolizumab (Tecentriq) for the treatment of patients with non–small cell lung cancer (NSCLC).
Latest:
Dr. Popat on the Investigation of Lurbinectedin in Second-line SCLCSanjay Popat, MBBS, FRCP, PhD, discusses the investigation of lurbinectedin as a second-line treatment for patients with small cell lung cancer.
